Detalles de la búsqueda
1.
Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.
J Virol
; 85(20): 10730-40, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21835798
2.
Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.
Mol Immunol
; 46(5): 917-26, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18952295
3.
Sequence-conserved and antibody-accessible sites in the V1V2 domain of HIV-1 gp120 envelope protein.
AIDS Res Hum Retroviruses
; 30(9): 927-31, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25051095
4.
Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.
PLoS One
; 9(2): e89987, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24587168
5.
Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.
Vaccine
; 32(39): 4916-24, 2014 Sep 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-25045827
6.
Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.
Virology
; 448: 363-74, 2014 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24314667
7.
Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies.
Adv Virol
; 2012: 803535, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22548061
8.
Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.
Virology
; 405(2): 513-23, 2010 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20663531
9.
Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.
AIDS Res Hum Retroviruses
; 25(4): 441-50, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19320565
10.
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
Virology
; 392(1): 82-93, 2009 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19632700
11.
Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
Virology
; 372(2): 233-46, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18061228
12.
Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.
J Virol
; 80(14): 6865-72, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16809292
13.
Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
J Virol
; 79(2): 780-90, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15613306
14.
Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
J Immunol
; 169(1): 595-605, 2002 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12077293
15.
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
J Virol
; 78(5): 2394-404, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14963135
16.
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
J Virol
; 76(18): 9035-45, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12186887
Resultados
1 -
16
de 16
1
Próxima >
>>